AU780261B2 - Methods of treating vascular diseases characterized by nitric oxide insufficiency - Google Patents

Methods of treating vascular diseases characterized by nitric oxide insufficiency Download PDF

Info

Publication number
AU780261B2
AU780261B2 AU14393/01A AU1439301A AU780261B2 AU 780261 B2 AU780261 B2 AU 780261B2 AU 14393/01 A AU14393/01 A AU 14393/01A AU 1439301 A AU1439301 A AU 1439301A AU 780261 B2 AU780261 B2 AU 780261B2
Authority
AU
Australia
Prior art keywords
nitrosated
antioxidant
administered
administering
hydralazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU14393/01A
Other languages
English (en)
Other versions
AU1439301A (en
Inventor
Michael D. Loberg
Joseph Loscalzo
Joseph A. Vita
Manuel Worcel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Nitromed Inc
Original Assignee
Boston University
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, Nitromed Inc filed Critical Boston University
Publication of AU1439301A publication Critical patent/AU1439301A/en
Application granted granted Critical
Publication of AU780261B2 publication Critical patent/AU780261B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU14393/01A 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency Ceased AU780261B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16223099P 1999-10-29 1999-10-29
US60/162230 1999-10-29
US17902000P 2000-01-31 2000-01-31
US60/179020 2000-01-31
PCT/US2000/029528 WO2001035961A1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Publications (2)

Publication Number Publication Date
AU1439301A AU1439301A (en) 2001-05-30
AU780261B2 true AU780261B2 (en) 2005-03-10

Family

ID=26858558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14393/01A Ceased AU780261B2 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Country Status (7)

Country Link
US (2) US6635273B1 (enExample)
EP (1) EP1244455B1 (enExample)
JP (1) JP2003514020A (enExample)
AU (1) AU780261B2 (enExample)
CA (1) CA2386954C (enExample)
DE (1) DE60042611D1 (enExample)
WO (1) WO2001035961A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US6465463B1 (en) * 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
DE60042611D1 (de) 1999-10-29 2009-09-03 Nitromed Inc Verfahren zur behandlung von gefässerkrankungen, dxid auszeichnen
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
WO2002017898A2 (en) * 2000-09-01 2002-03-07 Sacks Meir S Compositions and methods for inducing vasorelaxation
AU5939901A (en) * 2000-10-27 2002-05-06 Nitromed Inc Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
WO2002087508A2 (en) * 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
AU2008201838B2 (en) * 2001-05-02 2010-07-29 Nicox S.A. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
JP5506126B2 (ja) 2001-06-18 2014-05-28 ノーヴェン ファーマシューティカルズ インコーポレイテッド 経皮システムにおける加速した医薬の送達
FR2832634A1 (fr) * 2001-11-29 2003-05-30 Univ Pasteur Utilisation des isomeres l de derives aminoacides de l'hydroxyguanidine pour la production de no, compositions pharmaceutiques les contenant et utilisations pharmaceutiques
US20030170223A1 (en) * 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
AU2003283789A1 (en) * 2002-11-22 2004-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
EP1668008A4 (en) * 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
WO2005089639A2 (en) * 2004-03-16 2005-09-29 Talarico M D Matthew T Method for vascular dysregulation
EP1746882A4 (en) * 2004-03-31 2010-08-25 Nitromed Inc METHODS OF TREATING BLOOD DISORDERS USING NITRIC OXIDE DONOR COMPOUNDS
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
JP2008506716A (ja) * 2004-07-16 2008-03-06 ニトロメッド インコーポレーティッド 心不全に関連する組成物および方法
US7618594B2 (en) * 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US7560076B2 (en) * 2004-08-18 2009-07-14 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
JP4949661B2 (ja) * 2004-09-21 2012-06-13 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
EP1846380A4 (en) * 2005-01-21 2010-02-17 Nicox Sa HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME
WO2006128035A2 (en) * 2005-05-26 2006-11-30 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
CA2610694A1 (en) * 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
GB0517838D0 (en) * 2005-09-02 2005-10-12 Henderson Morley Plc Transdermal active principle delivery means
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
US20070098791A1 (en) 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
AU2006322656B2 (en) * 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
CA2634473A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
EP2005949A1 (en) 2006-03-13 2008-12-24 Kaneka Corporation Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent
CA2652135A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
AU2007267209A1 (en) 2006-05-29 2007-12-06 Nicox S.A. Nitrated heterocyclic compounds as endothelin receptor antagonist
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7862598B2 (en) 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
US20080312241A1 (en) * 2007-01-03 2008-12-18 Gilead Sciences, Inc. Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
CN101229156B (zh) * 2007-01-26 2010-07-07 鲁南制药集团股份有限公司 一种用于心血管系统疾病的药物组合物
US20080193385A1 (en) * 2007-02-08 2008-08-14 Todd Maibach Compositions and methods for treating neuropathy
CA2681308C (en) 2007-03-23 2015-11-24 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
WO2008128832A1 (en) * 2007-04-18 2008-10-30 Nicox S.A. Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8349262B2 (en) 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
WO2009097343A1 (en) 2008-01-28 2009-08-06 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
WO2009137071A1 (en) * 2008-05-09 2009-11-12 Duke University Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
JP5878866B2 (ja) 2009-06-22 2016-03-08 ゲノ エルエルシー 一酸化窒素治療
JP5995724B2 (ja) * 2009-11-20 2016-09-21 ゲノ エルエルシー 一酸化窒素送達システム
CN104997746A (zh) * 2015-08-24 2015-10-28 苏州艾伯特生物医药科技有限公司 一氧化氮供体型谷胱甘肽类化合物咀嚼片及应用
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN110856713B (zh) * 2018-08-23 2021-08-24 山东大学齐鲁医院 一种便携式治疗急性心衰发作的吸入式药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293565A (en) * 1979-06-13 1981-10-06 Sanol Schwarz-Monheim Gmbh Transdermal medication system for isosorbide dinitrate
US4584314A (en) * 1983-11-25 1986-04-22 Ciba-Geigy Corporation Lactone derivative, process for the preparation thereof, and use thereof in pest control
EP0968713A1 (en) * 1997-05-12 2000-01-05 Teikoku Seiyaku Co., Ltd. Plasters containing isosorbide nitrate

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584315A (en) * 1981-11-16 1986-04-22 The Upjohn Company Method of treating ischemic states
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4868179A (en) 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
EP0327263B1 (en) 1988-01-29 1994-09-07 PROCTOR, Peter H. Hair growth stimulation with nitroxide and other radicals
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
DE69229881T2 (de) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical Industries, Ltd. Tablette mit verzögerter freisetzung
NZ254112A (en) 1992-07-10 1997-06-24 Boots Co Plc Dioxocyclobutene derivatives; compounds, preparation and pharmaceutical compositions
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
DE4410997A1 (de) 1994-03-30 1995-10-26 Isis Pharma Gmbh Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
US5973011A (en) 1994-03-30 1999-10-26 Isis Pharma Gmbh Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
JPH0959152A (ja) 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤
DE19654895C2 (de) 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
ATE280574T1 (de) 1997-01-07 2004-11-15 Teijin Ltd Isosorbiddinitrat enthaltendes pflaster
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
IT1301759B1 (it) 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
EP1235563A2 (en) * 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
DE60042611D1 (de) 1999-10-29 2009-09-03 Nitromed Inc Verfahren zur behandlung von gefässerkrankungen, dxid auszeichnen
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293565A (en) * 1979-06-13 1981-10-06 Sanol Schwarz-Monheim Gmbh Transdermal medication system for isosorbide dinitrate
US4584314A (en) * 1983-11-25 1986-04-22 Ciba-Geigy Corporation Lactone derivative, process for the preparation thereof, and use thereof in pest control
EP0968713A1 (en) * 1997-05-12 2000-01-05 Teikoku Seiyaku Co., Ltd. Plasters containing isosorbide nitrate

Also Published As

Publication number Publication date
US6635273B1 (en) 2003-10-21
US7556824B2 (en) 2009-07-07
EP1244455A1 (en) 2002-10-02
EP1244455A4 (en) 2004-11-03
WO2001035961A1 (en) 2001-05-25
CA2386954A1 (en) 2001-05-25
US20040071766A1 (en) 2004-04-15
DE60042611D1 (de) 2009-09-03
AU1439301A (en) 2001-05-30
JP2003514020A (ja) 2003-04-15
EP1244455B1 (en) 2009-07-22
CA2386954C (en) 2011-12-13

Similar Documents

Publication Publication Date Title
AU780261B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) Composition for treating vascular diseases characterized by nitric oxide insufficiency
AU2006236103B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20100068267A1 (en) Compositions for treating vascular diseases characterized by nitric oxide insufficiency
EP1406608B1 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
AU2001259399A1 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
Yuan et al. Baicalein exerts neuroprotective effect against ischaemic/reperfusion injury via alteration of NF-kB and LOX and AMPK/Nrf2 pathway
AU2002338528A1 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
Wakade et al. Curcumin attenuates vascular inflammation and cerebral vasospasm after subarachnoid hemorrhage in mice
US20090118294A1 (en) Compositions and methods related to heart failure
JP2008535858A (ja) 心不全における遺伝リスク、すなわちｎｏｓ３の遺伝子変異の影響の評価方法
EP2680838A1 (en) TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
IL269623B1 (en) Cannabidiol derivatives as inhibitors of HIF prolyl hydroxylase activity
WO1999043308A2 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
AU2008201838B2 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
Macario et al. Inhibition of apoptosis prevents shear induced detachment of endothelial cells
AU2008200518A1 (en) Treatment of restenosis